How has Parkinson’s disease (PD) evolved over the years? Ryan Case, PhD, Senior Medical Director, recently shared his insights on the shifting landscape with pharmaphorum. The discussion explored his perspective on the latest advancements and exciting areas of innovation that are driving progress, as well as how MTPA’s guiding philosophy – the KAITEKI principle – shapes our work and commitment to people living with Parkinson’s disease. We applaud Ryan’s dedication to the PD community and are proud to have him on our team. Read the full article here: https://bit.ly/4fA9hZU
关于我们
We are taking on the challenges of complex and debilitating conditions and are committed to meeting the needs of people suffering from serious and often life-threatening illnesses. Today, we are focused on driving scientific discovery in many areas. Our focus remains on bringing treatment to people living with ALS as we strive to make a meaningful difference in their lives. Many people living with amyotrophic lateral sclerosis (ALS) have unmet medical needs. We are committed to doing our best to find solutions that may help address those needs. We continue to expand our work to deepen our understanding of ALS, explore potential biomarkers to aid in further research and seek new answers. Every day we tackle tough challenges in science and medicine. Our teams work diligently to develop smart options that will enable healthcare providers to offer safe and effective treatments for devastating illnesses. Please see our LinkedIn community guidelines here: https://www.mt-pharma-america.com/pdf/LinkedIn-Community-Guidelines.pdf
- 网站
-
https://www.mt-pharma-america.com/
Mitsubishi Tanabe Pharma America的外部链接
- 所属行业
- 制药业
- 规模
- 51-200 人
- 总部
- Jersey City，NJ
- 类型
- 私人持股
- 创立
- 2016
- 领域
- pharmaceutical products、amyotrophic lateral sclerosis、rare disease、innovation、research and development和global business
地点
-
主要
获取路线
US，NJ，Jersey City
Mitsubishi Tanabe Pharma America员工
-
Greg Fersko
Biopharma Strategy | Business Development | M&A | Market Access | Lifecycle Management
-
Howard Levine
Associate Director,Healthcare Intelligence | Digital Biomarkers | Wearables | Decentralized Clinical Trials ?? | Beyond the Pill ?? | Health IoT ??
-
Glenn Bubb
-
Lia Thornton
Sr. Director, Multichannel Marketing & Patient Support at Mitsubishi Tanabe Pharma America
动态
-
This #NationalFamilyCaregiversMonth, we recognize the dedication and compassion of caregivers, including those within our team like Greg Mitchell, Regional Business Director at MTPA.?? ? Over the span of four years, Greg's family of five quickly became 9, as he and his wife moved both of their parents from Texas to Pennsylvania to help care for them.?? ? As Greg puts it, “While there were many family dynamic changes with the blending of two families, now in caregiver-mode – this was the best decision we could have made.”? ? Read more about his story below as he sheds light on the challenges and rewards of caregiving.?? ? #TeamMTPA #NFCMonth??
-
Hear from?Nancy Bayerlein, Senior Director, Patient Engagement & Support, on the importance of reducing the burden placed on millions of family caregivers across the nation.?#NationalFamilyCaregiversMonth
“Family caregiver” — It’s a role that’s often overlooked in the discussion of disease, and nearly half of those currently taking on caregiving activities in the U.S. don’t identify with that label. In honor of #NationalFamilyCaregiversMonth, I delve into the importance of self-recognition and how broader awareness could help millions of Americans find the support they need. #TeamMTPA
-
This #VeteransDay we recognize those who have served in our nation’s military that now live with #ALS. Michael Flanagan, a U.S. Veteran living with this disease shares his story to help spread #ALSawareness. Thank you for your service!
-
Join us at the?Decentralized Trials & Research Alliance (DTRA)?2024 Annual Meeting! ? We're excited to announce that?Sharon Tamir, Senior Director, Digital Healthcare Innovation Business & Research Strategy, MTPA will be presenting at the Decentralized Trials & Research Alliance (DTRA) 2024 Annual Meeting on November 14! ? Sharon will share key insights and lessons learned from our "Go Digital" study, a remote-decentralized study paired with longitudinal clinic-entered registry data (MOVR study #MDA) for people with ALS. #DTRA2024
Excited to speak at the @DTRA2024 Annual Meeting in Boston on November 13-16! I'll present "The Go-Digital, a DCT Study: Monitoring Activity and fine motor skills assessment in people with ALS." I look forward to helping drive our shared mission of adopting decentralized methods in the community. #decentralizedclinicaltrials #DTRA2024
-
-
We’re honored to sponsor the Caregiver Action Network’s #NationalFamilyCaregiversMonth campaign.? ? The theme this year is “I Care…” which aims to highlight the importance of self-recognition and self-identity, an element of caregiving that we know is a significant barrier to caregivers accessing the information and resources necessary to support them throughout their caregiver journey.?? ? Learn more about I Care here: https://bit.ly/3BtVftS?
-
-
This #NationalFirstRespondersDay, we honor those dedicated to serving our communities, like Ken Sutcliffe, a former firefighter living with #ALS. Now, Ken serves in a different way by sharing his ALS story and spreading awareness of the disease.? ? Learn more about his story here: bit.ly/3NoZwS2??
-
-
Real-world data (#RWD) can help advance patient care strategies in rare diseases like #ALS. Explore our latest RWD findings on treatment outcomes and long-term function at #NEALS2024.?? ? Learn more: https://bit.ly/3YlTTtg?
-
At the Northeast ALS Consortium (NEALS) Annual Meeting, our team is showcasing 12 presentations on our latest #ALS research, including long-term function, efficacy, safety and mechanism of action studies.? ? Read more about our latest research at #NEALS2024 here: https://bit.ly/4088Hhh?
-
Our team is excited to be at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting, presenting three posters that evaluate #ALS treatment effectiveness, long-term safety and mechanism of action of an ALS treatment option.? ? We’ll be on-site engaging with industry leaders and researchers as we continue to discuss innovative research aimed at helping advance care for people living with ALS. #AANEM2024? ? Read more on our posters: https://bit.ly/4dLUhqC
-